[1]李艳玲,栾兆生.维甲酸在131I治疗分化型甲状腺癌中的应用[J].国际放射医学核医学杂志,2009,33(4):226-228.[doi:10.3760/cma.j.issn.1673-4114.2009.04.010]
　LI Yan-ling,LUAN Zhao-sheng.The application of retinoic acids in the 131I treatment with differentiated thyroid carcinoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2009,33(4):226-228.[doi:10.3760/cma.j.issn.1673-4114.2009.04.010]
点击复制

维甲酸在131I治疗分化型甲状腺癌中的应用(/HTML)
分享到：

《国际放射医学核医学杂志》[ISSN:1673-4114/CN:12-1381/R]

卷:
33
期数:
2009年第4期
页码:
226-228
栏目:
临床核医学
出版日期:
1900-01-01

文章信息/Info

Title:
The application of retinoic acids in the 131I treatment with differentiated thyroid carcinoma
作者:
李艳玲;  栾兆生
解放军第八十八医院核医学科, 泰安, 271000
Author(s):
LI Yan-ling;  LUAN Zhao-sheng
Department of Nuclear Medicine, Chinese PLA 88 Hospital, Shandong Taian 271000, China
关键词:
维甲酸; 甲状腺肿瘤; 碘放射性同位素; 近距离放射疗法
Keywords:
Retinoic acids; Thyroid neoplasms; Iodine radioisotopes; Brachytherapy
DOI:
10.3760/cma.j.issn.1673-4114.2009.04.010
摘要:
分化型甲状腺癌(DTC)细胞在进展过程中可发生失分化,以致于术后131I治疗或甲状腺素替代疗效差或无效,成为目前DTC治疗的难题之一。维甲酸作为维生素A的生物活性代谢产物,在调控细胞生长、分化、凋亡等生命活动中起着重要的作用。研究表明,维甲酸能够诱导失分化的DTC细胞再分化,提高肿瘤组织对131I的摄取能力,从而提高DTC治疗的疗效。
Abstract:
Differentiated thyroid carcinoma (DTC) can occur dedifferentiation in the progress of the process, which results in poor or no effect of the radioiodine therapy and the thyroid hormone replacement therapy after operation. It became one of the most thorny problem for the treatement of DTC now. Retinoic acids, the biologicallyactive metabolite of vitamin A, is of central importance for growth, differentiation,apoptosis and others vital movement of cells. It is demonstrated by studies that retinoic acids-induced redifferentiaon could raise the competence of tumor ingest 131I, accordingly raise effect of the DTC treatment.

参考文献/References:

[1] Elisei R,Pinchera A,Romei C,et ai.Expression of thyrotropin receptor (TSH-R),thyroglobulin,thyroperoxidase,and calcitonin messenger ribonucleic acids in thyroid carcinomas:evidence of TSH-R gene transcript in medullary histotype.J Clin Endocrinol Metab,1994,78(4); 867-871.
[2] Schmutzler C,Koehrle J.Innovative strategies for the treatment of thyroid cancer.Eur J Endocrinol,2000,143(1):15-24.
[3] Ringel MD,Anderson J,Souza SL,et al.Expression of the sodium iodide symporter and thyroglobulin genes are reduced in papillary thyroid cancer.Mod Pathol,2001,14(4):289-296.
[4] Russo D,Manole D,Arturi F,et al.Absence of sodium/iodide sym-porter gene mutations in differentiated human thyroid carcinomas.Thyroid,2001,11(1):37-39.
[5] Dohán O,Baloch Z,Bánrévi Z,et al.Rapid communication:Predom inant intracellular overexpression of the Na+/I-symporter(NIS) in a large sampling of thyroid cancer cases.J Clin Endocrinol Metab,2001,86(6):2697-2700.
[6] Grüning T,Tiepolts C,Zöphel K,et al.Retinoic acid for redifferentiation of thyroid cancer-does it hold its promise?.Eur J Endocrinol,2003,148(4):395-402.
[7] Klopper JP,Hays WR,Sharma V,et ai.Retinoid X receptor-gamma and peroxisome proliferator-activated receptor-gamma expression predicts thyroid carcinoma cell response to retinoid and thiazolidin edione treatment.Mol Cancer Ther,2004,3(8):1011-1020.
[8] Elisei R,Vivaldi A,Agate L,et al.All-trans-retinoic acid treatment inhibits the growth of retinoic acid receptor beta messenger ribonucleic acid expressing thyroid cancer cell lines but does not reinduce the expression of thyroid-specific genes.J Clin Endocrinol Metab,2005,90(4):2403-2411.
[9] Coelho SM,Vaisman M,Carvalho DP.Tumour re-differentiation effect of retinoic acid:a novel therapeutic approach for advanced thyroid cancer.Curr Pharra Des,2005,11(19):2525-2531.
[10] Hoang-Vu C,Bull K,Schwarz I,et al.Regulation of CD97 protein in thyroid carcinoma.J Clin Endocrinol Metab,1999,84(3):1104-1109.
[11] 潘中允.放射性核素治疗学.5版.北京:人民卫生出版社,2006:156-165.
[12] 桑士标,包建东,王栋梁,等.维甲酸诱导再分化治疗甲状腺癌26例疗效分析.苏州大学学报(医学版),2006,26(4):669-670.
[13] Simon D,Körber C,Krausch M,et al.Clinical impact of retinoids in redifferentiation therapy of advanced thyroid cancer:final results of a pilot study.Eur J Nucl Med Mol Imaging,2002,29(6):775-782.

相似文献/References:

[1]李盼丽,宋少莉.碘难治性分化型甲状腺癌靶向药物治疗进展[J].国际放射医学核医学杂志,2016,40(3):202.[doi:10.3760/cma.j.issn.1673-4114.2016.03.009]
　Li Panli,Song Shaoli.Radioactive iodine refractory differentiated thyroid cancer targeted therapy[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(4):202.[doi:10.3760/cma.j.issn.1673-4114.2016.03.009]
[2]杨珂,唐波,于夕荣,等.甲状腺癌131i治疗病房的辐射屏蔽计算与评价[J].国际放射医学核医学杂志,2015,39(5):405.[doi:10. 3760 / cma. j. issn. 1673-4114. 2015. 05. 012]
　yang ke,tang bo,yu xirong,et al.shielding calculation and assessment in 131i therapy for thyroid cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(4):405.[doi:10. 3760 / cma. j. issn. 1673-4114. 2015. 05. 012]
[3]陈立,陈跃.分化型甲状腺癌骨转移诊断及疗效评价的核素显像研究进展[J].国际放射医学核医学杂志,2016,40(6):452.[doi:10.3760/cma.j.issn.1673-4114.2016.06.010]
　Chen Li,Chen Yue.Diagnosis and evaluation of curative effect progress of radionuclide imaging methods in differentiated thyroid cancer of bone metastases[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(4):452.[doi:10.3760/cma.j.issn.1673-4114.2016.06.010]
[4]惠金子,赵德善.Tg、TgAb及TSH在分化型甲状腺癌术前的预测分析[J].国际放射医学核医学杂志,2015,39(2):110.[doi:10.3760/cma.j.issn.1673-4114.2015.02.002]
　Hui Jinzi,Zhao Deshan.The prediction of risk of differentiated thyroid carcinoma with preoperative serum thyroid stimulating hormone, thyrogiobulin and antithyroglobulin antibody[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(4):110.[doi:10.3760/cma.j.issn.1673-4114.2015.02.002]
[5]刘斌,潘明志.BRAF基因突变对甲状腺乳头状癌诊治价值的研究进展[J].国际放射医学核医学杂志,2015,39(2):154.[doi:10.3760/cma.j.issn.1673-4114.2015.02.011]
　Liu Bin,Pan Mingzhi.Advances in value of BRAF gene mutation on the diagnosis and treatment of papillary thyroid cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(4):154.[doi:10.3760/cma.j.issn.1673-4114.2015.02.011]
[6]胡斌,王锦锋,毛秋粉.18F-FDG PET/CT显像在Tg阳性131I全身显像阴性的分化型甲状腺癌患者中的应用价值[J].国际放射医学核医学杂志,2015,39(3):242.[doi:10.3760/cma.j.issn.1673-4114.2015.03.012]
　Hu Bin,Wang Jinfeng,Mao Qiufen.The application value of 18F-FDG PET/CT in patients with differentiated thyroid cancer of high thyroglobulin level and negative 131I whole body scan[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(4):242.[doi:10.3760/cma.j.issn.1673-4114.2015.03.012]
[7]刘鹏杰,唐铭,邓智勇,等.131I治疗儿童分化型甲状腺癌期间出现低钙血症伴癫痫发作一例[J].国际放射医学核医学杂志,2015,39(4):352.[doi:10.3760/cma.j.issn.1673-4114.2015.04.017]
[8]寇莹,刘建中,郝新忠,等.甲状腺癌131I治疗后全身扫描盆腔浓聚131I的临床分析[J].国际放射医学核医学杂志,2014,38(1):15.[doi:10.3760/cma.j.issn 1673-4114.2014.01.004]
　Kou Ying,Liu Jianzhong,Hao Xinzhong,et al.Analysis of pelvic 131I uptake after 131I whole body scan in patients with thyroid cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(4):15.[doi:10.3760/cma.j.issn 1673-4114.2014.01.004]
[9]李敬彦,蒋宁一.分化型甲状腺癌术后131I清甲治疗方法的相关问题[J].国际放射医学核医学杂志,2014,38(1):42.[doi:10.3760/cma.j.issn 1673-4114.2014.01.009]
　Li Jingyan,Jiang Ningyi.Issues related to radioactive iodine ablation in patients with differentiated thyroid carcinoma under-going thyroid surgery[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(4):42.[doi:10.3760/cma.j.issn 1673-4114.2014.01.009]
[10]成钊汀,谭建.分化型甲状腺癌术后患者131I治疗的辐射剂量与防护[J].国际放射医学核医学杂志,2014,38(2):110.[doi:10.3760/cma.j.issn.1673-4114.2014.02.010]
　Cheng Zhaoting,Tan Jian.Radiation dose and protection of differentiated thyroid carcinoma postoperative patients with 131I treatment[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(4):110.[doi:10.3760/cma.j.issn.1673-4114.2014.02.010]
[11]孟召伟,谭建.重组人促甲状腺激素和促再分化药物在分化型甲状腺癌中的应用[J].国际放射医学核医学杂志,2006,30(6):338.
　MENG Zhao-wei,TAN Jian.Application of recombinant human thyrotropin and redifferentiation drugs in differentiated thyroid cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2006,30(4):338.

备注/Memo

备注/Memo:
收稿日期:2009-03-18。
通讯作者:栾兆生,E-mail:luanzs@sina.com
更新日期/Last Update: 1900-01-01